Trials / Recruiting
RecruitingNCT07075471
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Conditions
Timeline
- Start date
- 2025-09-03
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-07-20
- Last updated
- 2025-11-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07075471. Inclusion in this directory is not an endorsement.